BridgeBio Said to Stir Buyout Interest From Pharma Firms (1)

BridgeBio Pharma Inc., which develops treatments for genetic diseases, is attracting takeover interest from bigger drug companies, according to people familiar with the matter.

Some large pharmaceutical companies are studying a potential acquisition of the Palo Alto, California-based biotech firm, the people said, asking not to be identified because the information is private.

Deliberations are ongoing, and there’s no certainty they will result in a transaction, the people said.

BridgeBio may decide to remain independent longer so it can benefit from the results of upcoming drug trials, some of the people said.

A representative for BridgeBio didn’t return ...